10.57

2.82% 0.3045

Ocular Therapeutix Inc (OCUL)

Overview News Price History Option Chain Financials Why OCUL Down? Discussions Forecast

Ocular Therapeutix Inc stock is traded at $10.57, with a volume of 340.65K. It is up +2.82% in the last 24 hours and up +7.32% over the past month. Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Previous Close:

$10.27

Open:

$10.19

24h Volume:

340.65K

Relative Volume:

0.30

Market Cap:

$1.60B

Revenue:

$58.44M

Net Income/Loss:

$-80.74M

P/E Ratio:

-8.8121

EPS:

-1.2

Net Cash Flow:

$-76.32M

1W Performance:

-6.55%

1M Performance:

+7.32%

6M Performance:

+71.15%

1Y Performance:

+223.93%

1-Day Range:

$10.07

$10.58

1-Week Range:

$9.76

$11.48

52-Week Range:

$1.995

$11.78

Ocular Therapeutix Inc Stock (OCUL) Company Profile

Name

Ocular Therapeutix Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

781-357-4000

Address

15 CROSBY DRIVE, BEDFORD, MA

Employee

267

Twitter

@OCUTX

Next Earnings Date

2024-11-05

Latest SEC Filings

OCUL's Discussions on Twitter

Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-21-23	Initiated	Robert W. Baird	Outperform
Aug-10-22	Resumed	Berenberg	Buy
Aug-10-21	Upgrade	H.C. Wainwright	Neutral → Buy
Dec-28-20	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-17-20	Initiated	Berenberg	Buy
Nov-13-20	Reiterated	Raymond James	Strong Buy
Aug-10-20	Reiterated	H.C. Wainwright	Buy
Mar-03-20	Upgrade	Raymond James	Outperform → Strong Buy
May-21-19	Downgrade	Cowen	Outperform → Market Perform
May-21-19	Reiterated	H.C. Wainwright	Buy
May-21-19	Downgrade	Raymond James	Strong Buy → Outperform
Dec-03-18	Reiterated	Cantor Fitzgerald	Overweight
Nov-15-18	Initiated	Raymond James	Strong Buy
Sep-07-18	Initiated	Piper Jaffray	Overweight
Oct-24-17	Initiated	Guggenheim	Buy
Jul-26-17	Initiated	H.C. Wainwright	Buy
Jul-12-17	Reiterated	Cantor Fitzgerald	Overweight
Jun-23-17	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-10-17	Initiated	Cantor Fitzgerald	Overweight
Nov-15-16	Reiterated	RBC Capital Mkts	Outperform
Aug-11-16	Initiated	JMP Securities	Mkt Outperform
Feb-17-16	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-23-15	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-13-15	Initiated	Morgan Stanley	Overweight

View All

Ocular Therapeutix Inc Stock (OCUL) Latest News

03:30 AM

Vanguard Group Inc's Strategic Reduction in Ocular Therapeutix I - GuruFocus.com

03:30 AM

Nov 02, 2024

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Nov 02, 2024

Oct 28, 2024

Ocular Therapeutix stock soars to 52-week high of $11.64 By Investing.com - Investing.com South Africa

Oct 28, 2024

Ocular Therapeutix (NASDAQ:OCUL) Reaches New 1-Year HighHere's What Happened - MarketBeat

Oct 28, 2024

Ocular Therapeutix stock soars to 52-week high of $11.64 - Investing.com India

Oct 28, 2024

Short Interest in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Drops By 18.1% - MarketBeat

Oct 28, 2024

Oct 26, 2024

Assenagon Asset Management S.A. Makes New Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat

Oct 26, 2024

Oct 21, 2024

Neuropathic Ocular Pain Pipeline Assessment 2024: Therapies, - openPR

Oct 21, 2024

Neuropathic Ocular Pain Pipeline Assessment 2024: Therapies, Clinical Trials, Therapies, and Key Companies Involved by DelveInsight | Ocular Therapeutix, Aldeyra Therapeutics, Aciex Therapeutics - Barchart

Oct 21, 2024

Allergic Conjunctivitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO - The Globe and Mail

Oct 21, 2024

Oct 20, 2024

Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last? - MSN

Oct 20, 2024

HC Wainwright Reaffirms “Buy” Rating for Ocular Therapeutix (NASDAQ:OCUL) - Defense World

Oct 20, 2024

Oct 18, 2024

SG Americas Securities LLC Purchases Shares of 45,187 Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat

Oct 18, 2024

Oct 17, 2024

Ocular Therapeutix (NASDAQ:OCUL) Sets New 52-Week HighTime to Buy? - MarketBeat

Oct 17, 2024

Oct 16, 2024

Ocular Therapeutix stock soars to 52-week high of $11.34 - Investing.com

Oct 16, 2024

Ocular Therapeutix stock soars to 52-week high of $11.34 By Investing.com - Investing.com UK

Oct 16, 2024

Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load? - Simply Wall St

Oct 16, 2024

Ocular Therapeutix (NASDAQ:OCUL) Stock Price Up 4.9%Here's Why - MarketBeat

Oct 16, 2024

Ocular Therapeutix shares hold as analyst reiterates Buy rating By Investing.com - Investing.com UK

Oct 16, 2024